Q3 Revenue Falls 19% to $24.6M as Net Loss Widens to $16.2M
RXST is trading near its 52-week low of $4.4 (4.3% above the low).
Summary
RxSight's Q3 revenue fell 19% to $24.6 million on 23,128 LAL units as competitive pressure persists, and the net loss widened to $16.2 million, or $0.39 a share, from $9.8 million a year ago. Gross margin dropped to 73.6% from 79.9% on higher inventory reserves and LAL/LDD costs. The Alcon collaboration contributed only $40 thousand of revenue in the quarter, so the partnership has not yet offset the core decline. Cash and short-term investments of $254.7 million include the $60 million Alcon payment, but the balance sheet also carries a $50 million refund liability. Management is betting on a nearly doubled sales force, new commercial leadership and a completed restructuring to stabilize the business; with the stock near its 52-week low, execution on those cost savings and any Alcon revenue ramp are the swing factors.
At the time of this announcement, RXST was trading at $4.59 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $190.9M. The 52-week trading range was $4.40 to $13.22. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.